We are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). Our second proprietary drug candidate, BIND-510, is a prostate-specific membrane antigen (PSMA)-targeted Accurin nanoparticle containing vincristine and is currently in preclinical development. The Company has collaborated or is collaborating with Pfizer, AstraZeneca, Roche, Merck, and Amgen to develop Accurins based on therapeutic payloads from their product pipelines.
View all » Recent Releases
Nov 19, 2014
BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium